Versor Investments LP Lowers Stock Holdings in Elevance Health, Inc. $ELV

Versor Investments LP lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 64.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,897 shares of the company’s stock after selling 3,500 shares during the quarter. Versor Investments LP’s holdings in Elevance Health were worth $613,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Blair William & Co. IL lifted its holdings in Elevance Health by 3.0% in the 2nd quarter. Blair William & Co. IL now owns 6,260 shares of the company’s stock worth $2,435,000 after buying an additional 180 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Elevance Health by 6.8% during the second quarter. IFP Advisors Inc now owns 704 shares of the company’s stock valued at $300,000 after buying an additional 45 shares during the last quarter. MGO One Seven LLC boosted its position in Elevance Health by 2.0% during the 2nd quarter. MGO One Seven LLC now owns 2,755 shares of the company’s stock worth $1,072,000 after acquiring an additional 53 shares during the period. Sequoia Financial Advisors LLC grew its position in Elevance Health by 2.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 6,880 shares of the company’s stock valued at $2,676,000 after buying an additional 163 shares in the last quarter. Finally, Moran Wealth Management LLC acquired a new position in shares of Elevance Health during the second quarter valued at approximately $7,558,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS estimate sharply to $4.75 from $3.48, signaling higher expected profitability for that quarter (Zacks retains a “Hold” rating).
• Positive Sentiment: Zacks also increased its Q3 2027 EPS view to $6.01 from $5.80, a modest upward revision for that quarter.
• Neutral Sentiment: Zacks trimmed Q4 2026 by a penny (to $3.43 from $3.44), a negligible change unlikely to move the share price materially.
• Neutral Sentiment: Market commentary is re‑examining ELV’s valuation — pieces weighing valuation vs. growth can be neutral unless they prompt revisions to investor positioning. Is Elevance Health (ELV) trading at an attractive valuation?
• Negative Sentiment: Zacks cut multiple near‑term quarterly estimates: Q1 2026 down to $10.40 (from $11.38), Q2 2026 down to $6.30 (from $8.51), and Q1 2027 down to $10.45 (from $13.30). These downgrades lower short‑term earnings visibility and may pressure the stock.
• Negative Sentiment: Zacks reduced full‑year forecasts: FY2026 to $25.53 (from $29.01) and FY2027 to $28.40 (from $31.89), which implies a weaker multi‑year earnings trajectory than previously expected. Zacks maintains a “Hold” rating.
• Negative Sentiment: Regulatory/legal risk has stepped into focus — a House Judiciary probe is examining aspects of Elevance’s valuation and business practices, introducing potential headline risk and uncertainty for investors. House Judiciary Probe Puts Focus On Elevance Health Valuation And Risks

Elevance Health Stock Performance

ELV stock opened at $330.07 on Thursday. The business’s 50-day moving average price is $351.84 and its two-hundred day moving average price is $331.27. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. The firm has a market cap of $72.85 billion, a PE ratio of 13.14, a P/E/G ratio of 1.81 and a beta of 0.50.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. Elevance Health’s dividend payout ratio is currently 27.23%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Guggenheim dropped their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. JPMorgan Chase & Co. increased their price target on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Sanford C. Bernstein lowered their target price on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Truist Financial cut their price target on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Finally, Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday. Twelve analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Elevance Health has an average rating of “Moderate Buy” and a consensus price target of $390.55.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.